Clinical Trials Browser

Phase 4 × Bortezomib × Lymphoid × Clear all

NCT02844322 2026-02-11

BDH-WM01

Phase 4 Completed

Waldenstrom Macroglobulinemia

NCT05137860 2022-01-18

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Phase 4 Unknown

LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma